K L Koch1, W L Hasler2, K P Yates3, H P Parkman4, P J Pasricha5, J Calles-Escandon6, W J Snape7, T L Abell8, R W McCallum9, L A Nguyen10, I Sarosiek9, G Farrugia11, J Tonascia3, L Lee3, L Miriel3, F Hamilton12. 1. Section on Gastroenterology, Wake Forest University, Winston-Salem, NC, USA. 2. Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA. 3. Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA. 4. Section of Gastroenterology, Temple University, Philadelphia, PA, USA. 5. Center for Neurogastroenterology, Johns Hopkins Bayview Medical Center, Baltimore, MD, USA. 6. Endocrinology Section, MetroHealth Medical Center, Cleveland, OH, USA. 7. California Pacific Medical Center, San Francisco, CA, USA. 8. Digestive and Liver Health, University of Louisville, Louisville, KY, USA. 9. Division of Gastroenterology, Texas Tech University, El Paso, TX, USA. 10. Division of Gastroenterology, Stanford University, Palo Alto, CA, USA. 11. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. 12. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA.
Abstract
BACKGROUND: In studies of diabetic gastroparesis, patients with type 1 and type 2 diabetes mellitus (T1DM, T2DM) are often combined for analyses. We compared gastroparesis severity, healthcare utilization, psychological function, and quality of life in T1DM vs T2DM gastroparesis patients. METHODS: Questionnaire, laboratory, and scintigraphy data from patients with gastroparesis and T1DM and T2DM from seven centers of the National Institute of Diabetes and Digestive and Kidney Diseases Gastroparesis Clinical Research Consortium Registry were compared at enrollment and after 48 weeks. Multiple regression models assessed baseline and follow-up differences between diabetes subtypes. KEY RESULTS: At baseline, T1DM patients (N = 78) had slower gastric emptying, more hospitalizations, more gastric stimulator implantations, higher hemoglobin A1c (HbA1c), and more anxiety vs T2DM patients (N = 59). Independent discriminators of patients with T1DM vs T2DM included worse gastroesophageal reflux disease, less bloating, more peripheral neuropathy, and fewer comorbidities (p ≤ 0.05). On follow-up, gastrointestinal (GI) symptom scores decreased only in T2DM (p < 0.05), but not in T1DM patients who reported greater prokinetic, proton pump inhibitor, anxiolytic, and gastric stimulator usage over 48 weeks (p ≤ 0.03). Gastrointestinal symptoms at baseline and 48 weeks with both subtypes were not associated with HbA1c, peripheral neuropathy, psychological factors, or quality of life. CONCLUSIONS & INFERENCES: Baseline symptoms were similar in T1DM and T2DM patients, even though T1DM patients had worse gastric emptying delays and higher HbA1c suggesting other factors mediate symptom severity. Symptom scores at 48 weeks decreased in T2DM, but not T1DM patients, despite increased medical and surgical treatment utilization by T1DM patients. Defining causes of different outcomes in diabetic gastroparesis warrants further investigation.
BACKGROUND: In studies of diabetic gastroparesis, patients with type 1 and type 2 diabetes mellitus (T1DM, T2DM) are often combined for analyses. We compared gastroparesis severity, healthcare utilization, psychological function, and quality of life in T1DM vs T2DM gastroparesispatients. METHODS: Questionnaire, laboratory, and scintigraphy data from patients with gastroparesis and T1DM and T2DM from seven centers of the National Institute of Diabetes and Digestive and Kidney Diseases Gastroparesis Clinical Research Consortium Registry were compared at enrollment and after 48 weeks. Multiple regression models assessed baseline and follow-up differences between diabetes subtypes. KEY RESULTS: At baseline, T1DM patients (N = 78) had slower gastric emptying, more hospitalizations, more gastric stimulator implantations, higher hemoglobin A1c (HbA1c), and more anxiety vs T2DM patients (N = 59). Independent discriminators of patients with T1DM vs T2DM included worse gastroesophageal reflux disease, less bloating, more peripheral neuropathy, and fewer comorbidities (p ≤ 0.05). On follow-up, gastrointestinal (GI) symptom scores decreased only in T2DM (p < 0.05), but not in T1DM patients who reported greater prokinetic, proton pump inhibitor, anxiolytic, and gastric stimulator usage over 48 weeks (p ≤ 0.03). Gastrointestinal symptoms at baseline and 48 weeks with both subtypes were not associated with HbA1c, peripheral neuropathy, psychological factors, or quality of life. CONCLUSIONS & INFERENCES: Baseline symptoms were similar in T1DM and T2DM patients, even though T1DM patients had worse gastric emptying delays and higher HbA1c suggesting other factors mediate symptom severity. Symptom scores at 48 weeks decreased in T2DM, but not T1DM patients, despite increased medical and surgical treatment utilization by T1DM patients. Defining causes of different outcomes in diabetic gastroparesis warrants further investigation.
Authors: Pankaj J Pasricha; Katherine P Yates; Linda Nguyen; John Clarke; Thomas L Abell; Gianrico Farrugia; William L Hasler; Kenneth L Koch; William J Snape; Richard W McCallum; Irene Sarosiek; James Tonascia; Laura A Miriel; Linda Lee; Frank Hamilton; Henry P Parkman Journal: Gastroenterology Date: 2015-08-21 Impact factor: 22.682
Authors: Christine de la Loge; Elyse Trudeau; Patrick Marquis; Peter Kahrilas; Vincenzo Stanghellini; Nicholas J Talley; Jan Tack; Dennis A Revicki; Anne M Rentz; Dominique Dubois Journal: Qual Life Res Date: 2004-12 Impact factor: 4.147
Authors: G Tougas; E Y Eaker; T L Abell; H Abrahamsson; M Boivin; J Chen; M P Hocking; E M Quigley; K L Koch; A Z Tokayer; V Stanghellini; Y Chen; J D Huizinga; J Rydén; I Bourgeois; R W McCallum Journal: Am J Gastroenterol Date: 2000-06 Impact factor: 10.864
Authors: Madhusudan Grover; Gianrico Farrugia; Matthew S Lurken; Cheryl E Bernard; Maria Simonetta Faussone-Pellegrini; Thomas C Smyrk; Henry P Parkman; Thomas L Abell; William J Snape; William L Hasler; Aynur Ünalp-Arida; Linda Nguyen; Kenneth L Koch; Jorges Calles; Linda Lee; James Tonascia; Frank A Hamilton; Pankaj J Pasricha Journal: Gastroenterology Date: 2011-02-04 Impact factor: 22.682
Authors: D A Revicki; A M Rentz; D Dubois; P Kahrilas; V Stanghellini; N J Talley; J Tack Journal: Aliment Pharmacol Ther Date: 2003-07-01 Impact factor: 8.171
Authors: Henry P Parkman; Goro Yamada; Mark L Van Natta; Katherine Yates; William L Hasler; Irene Sarosiek; Madhusudan Grover; Ron Schey; Thomas L Abell; Kenneth L Koch; Braden Kuo; John Clarke; Gianrico Farrugia; Linda Nguyen; William J Snape; Laura Miriel; James Tonascia; Frank Hamilton; Pankaj J Pasricha; Richard W McCallum Journal: Clin Gastroenterol Hepatol Date: 2018-11-04 Impact factor: 11.382
Authors: Henry P Parkman; Laura A Wilson; Gianrico Farrugia; Kenneth L Koch; William L Hasler; Linda A Nguyen; Thomas L Abell; William Snape; John Clarke; Braden Kuo; Richard W McCallum; Irene Sarosiek; Madhusudan Grover; Laura Miriel; James Tonascia; Frank A Hamilton; Pankaj J Pasricha Journal: Am J Gastroenterol Date: 2019-11 Impact factor: 10.864
Authors: Kenneth L Koch; William L Hasler; Mark Van Natta; Jorge Calles-Escandon; Madhusudan Grover; Pankaj J Pasricha; William J Snape; Henry P Parkman; Thomas L Abell; Richard W McCallum; Linda A Nguyen; Irene Sarosiek; Gianrico Farrugia; James Tonascia; Linda Lee; Laura Miriel; Frank Hamilton Journal: Neurogastroenterol Motil Date: 2019-10-01 Impact factor: 3.598
Authors: Jolien Schol; Lucas Wauters; Ram Dickman; Vasile Drug; Agata Mulak; Jordi Serra; Paul Enck; Jan Tack Journal: United European Gastroenterol J Date: 2021-04 Impact factor: 4.623